WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association
WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research Dr Lana Kandalaft from the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130407LanaKandalaftPODCASTLoRes.mp3]